Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Proposed [GID-TA10774] Expected publication date: TBC
Proposed [GID-TA10774] Expected publication date: TBC
Proposed [GID-TA10775] Expected publication date: TBC
Proposed [GID-TA10776] Expected publication date: TBC
Proposed [GID-TA10777] Expected publication date: TBC
Proposed [GID-TA10778] Expected publication date: TBC
Proposed [GID-TA10779] Expected publication date: TBC
Proposed [GID-TA10655] Expected publication date: TBC
Proposed [GID-TA10676] Expected publication date: TBC
Proposed [GID-TA10763] Expected publication date: TBC
Proposed [GID-TA10716] Expected publication date: TBC
Proposed [GID-TA10755] Expected publication date: TBC
Proposed [GID-TA10736] Expected publication date: TBC
Proposed [GID-TA10753] Expected publication date: TBC
Proposed [GID-TA10721] Expected publication date: TBC
Proposed [GID-TA10666] Expected publication date: 26 August 2021
Proposed [GID-TA10764] Expected publication date: TBC
Proposed [GID-TA10681] Expected publication date: TBC
Proposed [GID-TA10765] Expected publication date: TBC
Proposed [GID-TA10733] Expected publication date: TBC
Proposed [GID-TA10782] Expected publication date: 20 October 2021